Surveys
-
TIF STUDY | Desferioxamine Usage Survey
Desferioxamine is crucial in managing iron overload for many patients with thalassaemia and related blood conditions. Recently, the Thalassaemia International Federation (TIF) has received growing reports of shortages in Desferioxamine,…
Read More » -
-
TIF STUDY | Patient and Caregiver Perceptions of Thalassaemia Care in 2023
The study revealed that most patients with thalassaemia are receiving adequate treatment, including regular blood transfusions, chelation therapy, proper monitoring, and suitable imaging. Out of 2082 participants, 79.5% began transfusion…
Read More » -
-
TIF SURVEY | Sickle Cell Disease Patients’ Views on Oxbryta
OXBRYTA (voxelotor) is a prescription medicine used for the treatment of sickle cell disease (SCD) and constitutes the first aproved treatment that directly inhibits sickle hemoglobin polymerization, the root cause…
Read More » -
